Copyright: Panjin Tianyuan Pharmaceutical Co., Ltd. 
辽ICP备11017563号-1 
powered by  www.300.cn  jinzhou.300.cn

Panjin Tianyuan Pharmaceutical Co., Ltd. is a pharmaceutical industry which devotes itself to the developing, manufacturing,

distribution of herbal extracts

and drugs for external use.Panjin Tianyuan Pharmaceutical Co., Ltd., which has the self-operation export and import right,

is the Largest Professional Silymarin (Milk Thistle Extract) Manufacturer in china, now our Silymarin are exported to the world more than 30 countries or regions, such as Europe, United States, Canada, Japan, South Korea, Australia, India, Hong Kong, Taiwan, etc, favored by users.

The sales volume of our Silymarin become larger and larger, which occupy more than 50 percent of the total export of this kind of product in china...

 

 

Wonderful moment
盘锦天源药业

Wonderful moment

Wonderful moment
盘锦天源药业

Wonderful moment

Wonderful moment
盘锦天源药业

Wonderful moment

Wonderful moment
盘锦天源药业

Wonderful moment

The largest silymarin production line in China has been established in Taibai
盘锦天源药业

The largest silymarin production line in China has been established in Taibai

Release time:
2018-06-20 17:12
Abstract:
Recently,anannualproductionprojectof150tonssilymarininTaibaiCountyhaspassedtheacceptancetest.Expertsbelievethat"theproductionlinetechnologyisreasonable,theproductqualityisstable,theoveralltechnologyisintheleadinglevelinChina,andtheproductionscaleranksfirstinthecountry".TheplantingareaofmedicinalmaterialsinTaibaiCountyhasreachedmorethan80,000mu,and25%ofthepercapitanetincomeoffarmerscomesfromthetraditionalChinesemedicineindustry.ShaanxiSideCompanywasestablishedinTaibaiCountyasaprocessingenterpriseofChinesemedicinalmaterials.Itsself-developedsilymarinisaverypreciousChinesemedicinalmaterial.Lastyear,SideCompanyformallylaunchedasilymarinprocessingandproductionprojectwithatotalinvestmentof9.786millionyuan.TheprojectwascompletedandputintoproductioninOctoberofthatyear.Itcanproduceeightspecificationsofsilymarinproductswithanannualoutputof150tons,withanoutputvalueof39millionyuanandaprofitof5.23millionyuan.
American doctors have found that silymarin can treat mushroom poisoning
盘锦天源药业

American doctors have found that silymarin can treat mushroom poisoning

Release time:
2018-06-22 15:11
Abstract:
DoctorsatGeorgetownUniversityHospitalintheUnitedStatesrecentlytriedamethodtotreatmushroompoisoning,usingsilymarin,adrugthathassuccessfullycuredallpoisonedpatients,accordingtotheUSFoodSafetyWebsite.Itisknownthatsilymarinisextractedfromtheplantsilymarin,whichcanpreventthetoxinproducedbypoisonousmushroomsfromreachingtheliverandcausingdamage.AmanitatoxinisproducedbyAmanitafungus,whichistheculpritof95%ofmushroompoisoningintheUnitedStates.Atpresent,thetreatmentofmushroompoisoningisnotperfect,becausetherearefewercasesofpoisoningintheUnitedStates,sodoctorsdonothavemuchchancetofindeffectivetreatmentofmushroompoisoning.
Silymarin exports from Panjin account for more than half of the country's total
盘锦天源药业

Silymarin exports from Panjin account for more than half of the country's total

Release time:
2018-06-22 15:09
Abstract:
Theharvestseasonofsilymarinisapproaching.PanjinTianyuanPharmaceuticalCo.,Ltd.ismakinggreateffortstobuildanewworkshoptoexpandproductioncapacityandmeetordersfromallovertheworld.Afteryearsofdevelopment,PanjinCityhasformedauniquesilymarindeepprocessingindustrychain.Theannualproductioncapacityofsilymarinisnearly700tons,ofwhich300tonsareexported,accountingformorethan50%ofthetotalnationalexport.SilybumartichokehasbeenplantedinPanjinformanyyears,producingmorethan4000tonsofSilybumseedsannually.Atpresent,PanjinCityhas8silymarinprocessingenterprises,ofwhich2arecertifiedbyGMP.PanjinCityismakingfulluseoftheadvantagesofthelargestsilkwormprocessingbaseinChina,aimingatestablishingthewholeindustrialchainofsilkwormdeepprocessing,andstrengtheningthedevelopmentofnewproducts.Meanwhile,itisbuildingsilkwormdeepprocessingindustrialbasewithGaoshengEconomicZoneasthecarrier,throughjointventureswithWahaha,NongfuShanquanandotherlargeenterprisesathomeandabroad.Createtheleadingenterpriseofsilymarindeepprocessing.
Silymarin or diabetic nephropathy
盘锦天源药业

Silymarin or diabetic nephropathy

Release time:
2018-06-22 15:08
Abstract:
ArecentstudybyFallahzadehetal.intheJournalofAmericanJournalofNephrologyfoundanewpotentialagentforthetreatmentofdiabeticnephropathy:silymarin.Diabeticnephropathyisthemostcommoncauseofdiabeticrenalfailureworldwide.Fallahzadehandhiscolleaguesstudiedanewpotentialagentfortreatingdiabeticnephropathy:theherbalsilymarin,whichhasantioxidantandanti-inflammatoryproperties.Researchersconductedarandomized,double-blind,placebo-controlledclinicaltrialtoassessthepotentialefficacyandsafetyofsilymarin,withtheexceptionoftype2diabetesmellituspatientstreatedwithRASinhibitorsandpatientswithobviousnephropathy.Patientswithsignificantproteinuriaandoliguriawererandomlyassignedtosilymarin.Intheensuingdiscussion,researchersfoundrareopportunitiesandspecialchallengesinusingplantproductstotreatdiseases.Comparedwithtraditionalmedicines,plantsareusuallyamixtureofunknowningredients,andspecialattentionmustbepaidtotheanalysisofallpotentialactiveingredientsandbatch-to-batchchanges.